Wedbush Reiterates Outperform on Gossamer Bio, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides reiterates an Outperform rating on Gossamer Bio (NASDAQ:GOSS) and maintains a $6 price target.
March 06, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reiterates an Outperform rating on Gossamer Bio and maintains a $6 price target.
The reiteration of an Outperform rating and the maintenance of a $6 price target by a reputable analyst suggests a positive outlook for Gossamer Bio. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100